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To assess the eﬀect of the long-acting antipsychotic aripiprazole lauroxil (AL) on social and functional outcomes
compared with placebo in patients with acute schizophrenia, a post-hoc analysis was conducted. Patients with
acute schizophrenia were enrolled in a 12-week, double-blind, placebo-controlled eﬃcacy trial, and randomized
1:1:1 to receive AL 441 mg, AL 882 mg, or placebo every 4 weeks. Changes in social functioning using the 6- and
4-item Positive and Negative Syndrome Scale (PANSS) Prosocial subscales were evaluated. The Personal and
Social Performance (PSP) total score evaluated patients’ global improvement. Changes from baseline were
analyzed using mixed-eﬀect models repeat measurements. PANSS Prosocial subscale scores and PSP total score
improved signiﬁcantly with AL vs. placebo, without any dose-related diﬀerence in magnitude of response.
Signiﬁcant mean ± SE improvements in 6-item PANSS Prosocial scores from baseline to Day 85 were observed
for both individual active treatment groups (e.g., AL 441 mg and AL 882 mg groups) vs. placebo. There were
signiﬁcant changes in PSP total score from baseline to Day 85 for both AL doses vs. placebo. This post-hoc
analysis demonstrated a signiﬁcant improvement in social functioning with AL vs. placebo, as assessed by the
PANSS Prosocial subscale and PSP total score.

1. Introduction
Schizophrenia is a chronic illness and is one of the leading causes of
disability worldwide (Global Burden of Disease Study 2013
Collaborators, 2015). Symptoms often become evident in early adulthood and can have a signiﬁcant impact on social functioning during this
important developmental phase of life (Hollis, 2000). Up to two-thirds
of people with schizophrenia are unable to fulﬁll basic social roles, and
less than one-third maintain regular employment (Bellack et al., 2007),
often becoming socially isolated due to diﬃculties in maintaining social
relationships (Bellack et al., 2007). Impaired social skills may also
translate into poor health outcomes (Bellack et al., 2007) due to diﬃculties relating to healthcare professionals. Persistent social deﬁcits
with poor social outcomes over the long term are common
(Hollis, 2000). It is often reported that social and functional impairments are unresponsive to pharmacologic interventions (Guo et al.,
2010), but this ﬁnding may be misconstrued as absolute lack of response rather than partial, albeit incomplete, response.

Clinical practice guidelines for schizophrenia advocate for the improvement of social functioning as part of the treatment goals for patients with schizophrenia (Hasan et al., 2012; National Institute for
Health and Care Excellence, 2014). It should be noted, however, that
improvements in psychotic symptoms do not always correlate with an
improvement in functioning (Fleischhacker et al., 2005; San et al.,
2007; Ventura et al., 2011). Improvements in cognition and social
functioning are recognized as important indices of treatment success
that are not always linked to acute symptoms (Huang et al., 2012).
Aripiprazole lauroxil (AL) is a long-acting formulation of a prodrug
of aripiprazole approved for the treatment of schizophrenia
(Alkermes, Inc., 2018). The initial pivotal study demonstrated the efﬁcacy and safety of AL (441 mg and 882 mg doses) in a 12-week, randomized, double-blind, placebo-controlled study (Meltzer et al., 2015)
and in a 1-year safety extension study (Nasrallah et al., 2018). The aim
of this post-hoc analysis was to assess changes in social and functional
domains in patients with acute schizophrenia treated with AL compared
with placebo in the 12-week eﬃcacy study. Changes were assessed
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using validated clinical scales: the Positive and Negative Syndrome
Scale (PANSS) Prosocial subscales (Kay et al., 1987; Purnine et al.,
2000) and the Personal and Social Performance (PSP) scale
(Patrick et al., 2009).

and ≥71–100 (mild to no functional impairment) (Morosini et al.,
2000). A 10-point shift in score was considered to be clinically signiﬁcant (Nicholl et al., 2010), thus the proportion of patients with a 10point improvement was also evaluated.

2. Methods

2.3. Statistical analyses

This was a post-hoc analysis of patients with schizophrenia who
enrolled in an international, multicenter, 12-week, double-blind, phase
3, placebo-controlled trial (ClinicalTrials.gov identiﬁer: NCT01469039;
European Clinical Trial Database [EudraCT] Number: 2012-00345-15)
that was conducted across seven countries between December 2011 and
March 2014 (Meltzer et al., 2015). The study was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines by the International Conference on Harmonization,
1997. Institutional ethical review board or local ethics committee approval was obtained for each site. All patients provided informed
written consent before entering the study.

Analyses were carried out in all patients who were randomized,
received at least one dose of study drug and had at least one primary
eﬃcacy assessment. The change from baseline in PANSS Prosocial
scores and PSP total score were analyzed using mixed-eﬀect models
repeat measurements, and an unstructured variance-covariance matrix
was used to model the within-subject variability. The model included
baseline as a covariate. In addition, the analysis of PSP category shift
was performed based on the last observation carried forward for imputation of missing data. Cohen's d (Cohen, 1988) was used to assess
overall treatment eﬀect sizes for the PANSS Prosocial score and PSP
score. According to Cohen, 0.2 is considered a small eﬀect size, 0.5 is a
medium eﬀect size and 0.8 is a large eﬀect size (Cohen, 1988; Fritz
et al., 2012). Additionally, for categorical outcomes, we calculated the
number-needed-to-treat (NNT), dividing 1 by the risk diﬀerence.

2.1. Patients
Patients with acute schizophrenia (n = 623) were randomized in a
1:1:1 ratio to receive AL 441 mg (aripiprazole 300 mg equivalent); AL
882 mg (aripiprazole 600 mg equivalent); or placebo. Doses were administered intramuscularly once every 4 weeks for 12 weeks.
Patients assigned to one of the active AL arms also received oral
aripiprazole 15 mg daily for the ﬁrst 3 weeks after randomization to
achieve early therapeutic exposure to aripiprazole from the combined
release of AL and oral aripiprazole; placebo-arm patients received
matched oral study medication.
Full details of the study design and patient eligibility criteria have
been described elsewhere (Meltzer et al., 2015). Brieﬂy, the study enrolled patients who were hospitalized for the treatment of an acute
exacerbation of schizophrenia. Patients were included if they were aged
18–70 years, with a primary diagnosis of schizophrenia according to the
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, had
been an outpatient for >3 months during the year before enrolment,
and had a PANSS total score of 70–120. Major exclusion criteria were
the presence of another primary psychiatric diagnosis, clinically signiﬁcant medical illness, history of treatment resistance, history of poor
response to oral aripiprazole, being pregnant or lactating or unable or
unwilling to consent (Meltzer et al., 2015).

3. Results
In total, 623 patients were enrolled into the study and randomized
1:1:1 to AL 441 mg, AL 882 mg, or placebo, of which 596 patients were
included in this post-hoc analysis. A full CONSORT diagram and patient
disposition were published in Meltzer et al. (2015).
Patient demographics and baseline social and functional outcome
scores are presented in Table 1. Approximately two-thirds of patients
were male, and the sample had a mean age of 39.0 years. Further details
on patient demographics are available in Meltzer et al. (2015).
3.1. Positive and Negative Syndrome Scale (PANSS) Prosocial subscales
Statistically signiﬁcant improvements in the 6-item PANSS Prosocial
scores were observed as early as Day 8 and were maintained through to
Day 85 for both doses of AL (mean ± standard error [SE] decrease from
baseline to Day 85 of ‒6.6 ± 0.4 and ‒6.4 ± 0.4 points for AL 441 mg
and AL 882 mg, respectively) compared with placebo (−3.4 ± 0.5
points; p < 0.0001 for both doses) (Fig. 1). Similar statistically signiﬁcant improvements in the 4-item modiﬁed PANSS Prosocial scores
were observed as early as Day 8 and maintained through Day 85 for
both AL doses: the mean ± SE decrease from baseline to Day 85 was
‒3.1 ± 0.3 and ‒3.2 ± 0.2 points in patients administered AL 441 mg
and AL 882 mg, respectively, compared with placebo (−1.6 ± 0.3
points; p < 0.0001 for both doses) (Supplemental Fig. 1). The overall
treatment eﬀect sizes for PANSS Prosocial scores with AL 441 mg or AL
882 mg compared with placebo were Cohen's d = 0.52 and 0.49, respectively.

2.2. Clinical assessments of social and functional outcomes
Social and functional outcomes were assessed using selected items
from the PANSS. The PANSS Prosocial subscale, previously developed
as a sensitive measure of social functioning, has been validated in patients with schizophrenia (Harvey et al., 2015; Kay et al., 1987; Loebel
et al., 2004; Purnine et al., 2000). The following PANSS items were
included in the 6-item Prosocial subscale: G16 [active social avoidance]; N2 [emotional withdrawal]; N4 [passive social withdrawal]; N7
[stereotyped thinking]; P3 [hallucinatory behavior]; and P6 [suspiciousness/persecution] with standard PANSS anchoring from absent (1)
to extreme (7). The following 4-item PANSS Prosocial subscale was also
assessed (Docherty et al., 2010): G16 [active social avoidance]; N2
[emotional withdrawal]; N4 [passive social withdrawal]; and N5 [difﬁculty in abstract thinking].
Other functional outcome domains were assessed using the PSP
scale, a validated, clinician-administered scale that utilizes clinical interview of the patient and caregiver combined with clinical observation
to measure global and personal social functioning on a 0–100 scale
(Patrick et al., 2009). PSP was assessed as both change in total score
and proportion of patients with categorical shifts in PSP score, deﬁned
as PSP scores of 0–30 (severe functional impairment), ≥31–50 (marked
functional impairment), ≥51–70 (moderate functional impairment),

3.2. Personal and Social Performance (PSP) scores
Patients who received AL for 12 weeks experienced statistically and
clinically signiﬁcant functional improvements, as assessed by the PSP
total score (Fig. 2). Change in PSP total score was statistically signiﬁcant for both doses of AL (mean ± SE improvement from baseline to
Day 85 of 12.8 ± 1.1 and 14.0 ± 1.0 points for AL 441 mg and AL
882 mg, respectively) compared with placebo (5.2 ± 1.1-point improvement from baseline to Day 85; p < 0.0001 for both doses). Patients in the placebo group exhibited non-signiﬁcant changes in functional status, as assessed by the PSP total score (Fig. 2). Clinically
signiﬁcant improvements in functioning were observed as early as Day
29 (mean ± SE improvement from baseline to Day 29 of 10.3 ± 1.0
and 11.4 ± 0.9 points for AL 441 mg and AL 882 mg, respectively;
p < 0.0001 for both doses) and were maintained at Day 85 (Fig. 2). The
177
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overall treatment eﬀect sizes for PSP total score with AL441 mg or AL
882 mg compared with placebo were Cohen's d = 0.51 and 0.59, respectively.
A signiﬁcantly greater proportion of patients treated with AL exhibited a clinically signiﬁcant improvement in functioning, as measured
by a ≥ 10-point shift from baseline in PSP score, compared with placebo. Overall, by Day 85, 57.2% and 60.5% of patients in the AL
441 mg (n = 103/180) and AL 882 mg groups (n = 112/185), respectively, compared with 30.7% (n = 55/179) of patients in the placebo
group, experienced a clinically signiﬁcant improvement in functioning,
translating into an NNT = 3.8 for AL 441 mg and NNT = 3.4 for AL
882 mg. A signiﬁcant diﬀerence in the proportion of patients demonstrating a ≥ 10-point shift in PSP total score was observed as early as
Day 8.
Functional status, as assessed by PSP total score changes by category, is shown in Fig. 3. Patients who received AL 441 mg showed an
overall trend in change from marked/moderate to mild/moderate
functional impairment. Patients who received AL 882 mg showed a
trend in change from severe/marked to moderate/mild functional impairment. Fewer patients treated with AL 882 mg were severely functionally impaired at Day 85 compared with those treated with AL
441 mg (0.5% vs 4.4%, respectively), with the highest proportion in the
placebo group (8.4%). Patients who received placebo showed a trend
toward a change from marked/moderate to moderate/mild functional
impairment.

Table 1
Baseline patient demographic and psychiatric characteristics.
Characteristic

AL 441 mg
(n = 207)

AL 882 mg
(n = 208)

Placebo
(n = 208)

Men, n (%)
Age, mean (SD), years
BMI, mean (SD), kg/m2
Race, n (%)
White
Black/African American
Asian
Other
PANSS total score, mean
(SD)a
6-item PANSS Prosocial
subscale score, mean
(SD)a, b
Modiﬁed 4-item PANSS
Prosocial subscale score,
mean (SD)a,b
PSP total score, mean (SD)a
PSP total score, n (%)a,c,d
1–30
31–50
51–70
71–100
CGI-S score, mean (SD)a

141 (68.1)
39.9 (10.1)
27.7 (5.3)

143 (68.8)
39.7 (11.1)
27.3 (5.7)

139 (66.8)
39.5 (11.9)
27.0 (5.1)

99 (47.8)
83 (40.1)
24 (11.6)
1 (0.5)
92.6 (10.2)

98 (47.1)
81 (38.9)
28 (13.5)
1 (0.5)
92.0 (10.8)

94 (45.2)
84 (40.4)
29 (13.9)
1 (0.5)
93.9 (11.3)

22.8 (3.2)

22.5 (3.4)

23.0 (3.6)

14.5 (2.7)

14.5 (3.0)

14.9 (2.9)

50.4 (12.1)

50.9 (12.5)

48.6 (12.8)

7 (3.6)
102 (52.3)
78 (40.0)
8 (4.1)
4.9 (0.6)

10 (4.9)
104 (51.2)
75 (37.0)
14 (6.9)
4.9 (0.6)

16 (8.2)
101 (51.8)
68 (34.9)
10 (5.1)
4.9 (0.6)

AL, aripiprazole lauroxil; BMI, body mass index; CGI-S, Clinical Global
Impression-Severity; PANSS, Positive and Negative Syndrome Scale; PSP,
Personal and Social Performance; SD, standard deviation.
a
Patients in the post-hoc analysis population for AL 441 mg, n = 196; for AL
882 mg, n = 204; for placebo, n = 196.
b
Each PANSS item is rated from absent (1) to extreme (7) (Purnine et al.,
2000); the 6-item PANSS Prosocial subscale score range is 6–42 and 4-item
PANSS Prosocial subscale score range is 4–28.
c
Measurement for one patient missing from each study group.
d
PSP scores on a scale of 0–100: 0–30 = severe functional impairment,
≥31–50 = marked functional impairment, ≥51–70 = moderate functional
impairment, and ≥71–100 = mild to no functional impairment
(Morosini et al., 2000).

3.3. Adverse events
Discontinuation for adverse eﬀects was low with both doses of AL
(AL 441 mg: 6.8%, AL 882 mg: 2.9% and placebo: 17.9% of patients)
(Meltzer et al., 2015). AL had an adverse-event proﬁle that was consistent with that of oral aripiprazole (Meltzer et al., 2015). The frequency of injection-site reactions was low and predominantly described
as injection-site pain associated with the ﬁrst injection in the gluteal
muscle (Meltzer et al., 2015). Full details of the adverse events observed
have been provided in Meltzer et al. (2015).

Fig. 1. Change in PANSS Prosocial Subscale (6-item) Scores over time. *p < 0.01; **p < 0.005; ***p < 0.001; ****p < 0.0001, p values vs placebo.
Each PANSS item is rated from absent (1) to extreme (7) (Purnine et al., 2000), such that the score range is 6–42. AL, aripiprazole lauroxil; LS, least squares; MMRM,
mixed-eﬀect model repeat measurements; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation; SE, standard error.
178
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Fig. 2. Change from baseline to Day 85 in PSP total score over time. *p < 0.0001, p-values vs placebo. PSP scores on a scale of 0–100: 0–30 = severe functional
impairment, ≥31–50 = marked functional impairment, ≥51–70 = moderate functional impairment, and ≥71–100 = mild to no functional impairment
(Morosini et al., 2000). AL, aripiprazole lauroxil; LS, least squares; MMRM, mixed-eﬀect model repeat measurements; PSP, Personal and Social Performance; SD,
standard deviation; SE, standard error.

Fig. 3. Frequency of PSP categories at baseline and at Day 85
AL, aripiprazole lauroxil; PSP, Personal and Social Performance.

4. Discussion

AL achieved a clinically signiﬁcant 10-point improvement in PSP score
compared with placebo (NNT = 3.4 to 3.8), and more patients experienced a shift to categories of improved social functioning.
Measurement of social functioning in patients with schizophrenia is
a complex topic due to the multifaceted nature of the condition, and
thus challenges with the use of assessment scales must be acknowledged
(Brissos et al., 2011). In fact, while a wide selection of assessment instruments are available, there is a lack of consensus regarding the deﬁnition and measurement of social functioning in schizophrenia
(Figueira and Brissos, 2011). The present post-hoc analysis utilizes data
from the PSP scale, a validated, clinician-administered scale that measures global and personal social functioning (Patrick et al., 2009), in

In this post-hoc analysis, patients with acute schizophrenia who received AL had signiﬁcantly improved PANSS Prosocial and modiﬁed
PANSS Prosocial scores compared with patients who received placebo
as early as Day 8, and the improvements were maintained throughout
the 12-week duration of the study. Although this study was not designed as an evaluation of the shorter 4-item modiﬁed Prosocial scale, it
appears that the 4-item scale was adequately sensitive to change over
time, as well as active drug/placebo diﬀerences. The PSP scores showed
a similar trajectory of improvement at Day 8 until the end of the 12week study. A signiﬁcantly greater proportion of patients administered
179

Psychiatry Research 274 (2019) 176–181

C.U. Correll, et al.

the PANSS to deﬁne social functioning is a limitation, because a limited
number of subdomains have been assessed in this study and they have
not been independently validated in patients with schizophrenia.
However, the broad use of PANSS in clinical studies in the literature
suggests that these ﬁndings can be compared in the future with any
post-hoc analysis that may be conducted using data from other longerterm studies investigating the impact of treatment on social functioning. Furthermore, it has been suggested that exploratory analysis of
supportive eﬃcacy endpoints may provide more intuitive clinical information than absolute point changes on clinical rating scales on the
relative eﬃcacy of AL compared with placebo (Citrome et al., 2017). As
post-hoc analyses are limited in their application and may be subject to
an increased risk of bias, long-term, prospective studies focusing on
social functioning are required to conﬁrm the present outcome.
In conclusion, patients with acute schizophrenia who received 12
weeks of treatment with AL showed signiﬁcant improvements in social
functioning translating into a medium eﬀect size compared with placebo, as assessed by the PANSS Prosocial subscales and the PSP scores.

addition to the PANSS Prosocial and modiﬁed Prosocial subscales, reﬂecting emotional withdrawal and a lack of social interaction, with the
aim of covering a broad range of aspects of social functioning. However,
it has previously been acknowledged that functional recovery in schizophrenia is impacted by a range of factors, and the relationship of an
improvement in a PANSS-derived measure of social functioning on
overall functional recovery is not fully understood (Docherty et al.,
2010).
Social and functional impairments in patients with schizophrenia
are diﬃcult to treat and may not correlate with improvements in
clinical symptoms (Fleischhacker et al., 2005; Hasan et al., 2012; San
et al., 2007; Ventura et al., 2015); however, this study demonstrated
that the overall eﬃcacy of AL (Meltzer et al., 2015) translated into
improved social functioning for patients with acute schizophrenia.
Treatment with AL has further been reported to reduce agitation and
hostility (Citrome et al., 2016). Improvements in social function have
also been reported with oral aripiprazole (Docherty et al., 2010). Enhancing social functioning for patients with acute schizophrenia may
assist in maintaining social relationships, reducing isolation, and improving employment opportunities (Bellack et al., 2007).
Other studies have also demonstrated improvements in PSP with the
long-acting formulation of aripiprazole. In two long-term studies (38
and 52 weeks) investigating the treatment of patients with acute schizophrenia, aripiprazole long-acting formulation was reported to signiﬁcantly reduce PSP scores (Fleischhacker et al., 2014). Notably, patients in the present study had lower mean baseline PSP total scores (50
points; indicating marked to severe functional impairment) compared
with >60 (indicating moderate functional impairment) in the aripiprazole long-acting injection study (Fleischhacker et al., 2014). Interestingly, although increased PSP scores were observed during the
dose-stabilization phase (12 weeks), a further reduction in PSP score
was reported during the double-blind phase (52 weeks)
(Fleischhacker et al., 2014). The results of the present study are consistent with the improvement in the PSP social subdomains with aripiprazole long-acting injection (Fleischhacker et al., 2014).
The improvement in PSP total score for AL is similar to that reported
in acute patients treated with paliperidone palmitate. In a 6-month,
open-label study of monthly paliperidone palmitate in patients with
acute schizophrenia, previously unsuccessfully treated with oral antipsychotics, PSP total scores increased by ≥10 points over the study
period (Hargarter et al., 2015). In the 28-week QUALIFY study, patients
with stable schizophrenia receiving once-monthly long-acting aripiprazole reported greater improvements in functional and quality-oflife outcomes, and signiﬁcantly greater improvements in social initiative, than patients treated with paliperidone palmitate (Potkin et al.,
2017).
A limitation of this post-hoc study was the short 12-week duration of
the parent study (Meltzer et al., 2015). Moreover, the use of oral aripiprazole supplementation for the ﬁrst 21 days provides the therapeutic concentrations that account for the early signiﬁcant improvements (Day 8) in the PANSS Prosocial subscales scores. Since patients
had an acute exacerbation at baseline, some of the social and functional
improvements could have been secondary to an improvement in positive symptoms. However, research has indicated that social and functional impairments in schizophrenia patients may not correlate that
closely with clinical symptom improvements (Fleischhacker et al.,
2005; Hasan et al., 2012; San et al., 2007; Ventura et al., 2015). Furthermore, achieving the full degree of functional improvement may
take longer than 12 weeks and likely diﬀers based on the treatment
setting and whether psychosocial interventions are paired with pharmacological treatments. Nevertheless, although patients had to be
hospitalized at baseline, they could be discharged and treated as outpatients as early as 2 weeks after the ﬁrst injection, and based on investigator judgment. Another limitation was that at some sites, the
same rater completed the PANSS and PSP, while at others, it could have
been completed by diﬀerent raters. Additionally, the use of subscales of
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